

# Comprehensive Research Plan: Treatment of Chronic Hepatitis B

Environmental Scan

November 7, 2014

## ODPRN Drug Class Review Proposal: Environmental Scan

### Study Title: Treatment of Chronic Hepatitis B

- Objectives:**
1. To summarize the pharmacy benefit programs for treatments of chronic hepatitis B in Ontario, across Canada and in select international jurisdictions
  2. To determine the impact of different drug reimbursement schemes for treatments of chronic hepatitis B on patient access, quality of life and/or utilization and costs
  3. To summarize the guidelines for treatment of chronic hepatitis B

- Study Questions:** In patients treated for chronic hepatitis B:
1. How are treatments currently being accessed in publicly funded programs across Canada as well as internationally?
  2. What is the impact of different drug reimbursement schemes for treatments on patient access, quality of life and/or utilization and costs?
  3. Does sex, gender, immigrant status or socioeconomic status play an important role in any of the analyses described?

### Objective 1: Pharmacy Benefit Programs in Ontario, across Canada and internationally

**Study Design:** Design: summary of available information available through the Internet; interviews with individuals at the government agencies responsible for the public drug plan  
Data sources: Internet, direct contact with individuals

- Study Population:**
- Canada: provincial/territorial public plans
  - England, Wales, Northern Ireland, Scotland: NICE (National Institute for Health and Care Excellence)
  - Australia: Pharmaceutical Benefits Scheme
  - United States: Medicare, Veterans Affairs
  - New Zealand: PHARMAC (Pharmaceutical Management Agency)

- Intervention:**
- Treatments for Chronic Hepatitis B
    - Standard interferon, Pegylated interferon, Lamivudine, adefovir, entecavir, telbivudine, tenofovir

- Outcome(s) of Interest:**
- Drug Reimbursement Criteria and Policies:
- Change of EAP criteria
  - Other Reimbursements ( Limited Use vs. general benefit)

### Objective 2: Impact of different drug reimbursement schemes

**Study Design:**                    Design: Literature review  
     Data sources: Medline, EMBASE, Cochrane Collection, Grey literature

**Study Population:**            Treatment of Chronic Hepatitis B

**Intervention:**                 Various drug reimbursement schemes, including general benefits, step therapy, special authorization

**Outcome(s) of Interest:**        Indirect/direct measurements of clinical outcomes, patient satisfaction, quality of life, utilization and/or costs

### Objective 3: Guidelines for treatment of chronic hepatitis B

**Study Design:**                    Design: Literature review  
     Data sources: Medline, EMBASE, Cochrane Collection, Grey literature

**Study Population:**            Treatment of Chronic Hepatitis B

**Intervention:**                 Guidelines/recommendations for the treatment of Chronic Hepatitis B

**Outcome(s) of Interest:**        Published guidelines by various organizations including Canadian Consensus (2012), PHAC recommendations (2012)